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Urokinase synthesis and binding by glomerular epithelial cells in
culture. Fibrin deposits are frequently observed in the course of
proliferative extracapillary glomerulonephritis and could be related to a
defective local fibrinolysis. We studied human glomerular epithelial
cells in culture which were found to release mainly a urokinase-type
plasminogen activator (u-PA) identified on zymography by its molecular
weight (53 kD), its plasminogen activator activity, and its neutralization
by specific polyclonal anti-u-PA lgG. Trace amounts of tissue-type
plasminogen activator (t-PA) complexed to a plasminogen activator
inhibitor type I (PAl-I) were identified with specific antibodies. Specific
binding sites were found at the surface of glomerular epithelial cells
(kD: 2.l0- M), partially occupied by secreted u-PA. The spontaneous
u-PA activity of the culture medium conditioned by glomerular epithe-
hal cells was very low, suggesting that u-PA was released in its inactive
single chain proenzyme form (SC-u-PA). After activation of SC-u-PA
by plasmin, u-PA activity of the culture medium was found to increase
in a time- and dose-dependent manner when cells were incubated with
phorbol myristic acetate (PMA). This effect was inhibited by H7. a
protein kinase C inhibitor. Stimulation of u-PA synthesis by PMA was
also observed in two different epithelial tubular cell lines, LLC-PK I and
MDCK cells. However, 8 bromo cyclic AMP which increased u-PA
release by LLC-PKI cells was found to inhibit u-PA release by
PMA-stimulated glomerular epithelial cells and MDCK cells. By North-
ern blot analysis we found that PMA induced an increase of u-PA
mRNA level in glomerular epithelial cells and that cyclic AMP had an
opposite effect. Thus the fibrinolytic activity could be regulated by
hormones and local mediators which activate these intracellular path-
ways.
Urokinase-type plasminogen activator (u-PA) is a serine
protease with phasminogen activator (PA) activity [1]. Its pri-
mary amino acid sequence has been determined [2, 31, and
human, murine and porcin u-PA genes have been cloned [4—61.
It is released as an inactive single-chain proenzyme (53 kD), and
can be extracellularly activated by limited proteolysis into a
two-chain active form (53 kD). A 33 kD active u-PA is also
found in biological fluids [7—9]. In contrast to tissue-type
plasminogen activator (t-PA) u-PA can enhance plasmin forma-
tion in the absence of fibrin. Its role has been studied in many
organs and systems: it is involved in tissue repair [10], cell
migration [II], tumor dissemination [12] and probably also in
intravascular fibrinolysis, although t-PA seems to be the main
intravascular plasminogen activator. Recently two specific in-
hibitors of plasminogen activators (PAl) have also been identi-
fied and purified [13, 141.
Renal epithelial cells seem to be the main source of urinary
urokinase. Its role is not completely known but could be the
generation of a local, regulated, proteolytic activity to prevent
clot formation and fibrin accumulation in the urinary space of
the glomerulus and the tubules. We have previously shown that
cultured glomerular epithelial cells from normal human kidneys
contain u-PA [15]. These cells have been shown to accumulate
in the Bowman space [161 sometimes with infiltrating macro-
phages [17] during the course of extracapillary glomerulone-
phritis. These crescent formations are usually associated with
persistent fibrin deposits, possibly related to local defective
fibrinolytic activity. Specific u-PA receptors have been de-
scribed in human monocytes and monocyte-like cells [18, 19].
Receptor-bound u-PA is not internalized and confers surface
u-PA activity on monocytes that is insensitive to u-PA inhibi-
tors [20, 211. Other cell types, which synthesize u-PA, have
been shown to have specific u-PA receptors at their surface
(reviewed in I). We thus looked for specific u-PA receptors at
the surface of glomerular epithelial cells and studied the regu-
lation of u-PA synthesis in these cells. We compared them to
epithelial tubular cell lines, the LLC-PKI and the MDCK,
which retain some properties of respectively proximal and
distal tubule. In both these cell lines, u-PA synthesis and
release have been shown to be stimulated by phorbol esters [22,
23] which are known to activate protein kinase C [24]. In
LLC-PK 1, u-PA synthesis has also been shown to be increased
by cyclic AMP and by hormones such as calcitonin or arginin
vasopressin whose intracellular effects are mediated by cyclic
AMP generation [25, 26]. We demonstrate here that human
glomerular epithelial cells in culture have specific membrane
receptors for u-PA and that phorbol myristate acetate increases
the synthesis of u-PA whereas cyclic AMP inhibits this effect.
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Materials
The following materials were obtained from the sources
indicated: collagenase type IV and Triton X-100 (Sigma Chem-
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ical Co., St. Louis, Missouri, USA), bovine thrombin from
Hoffman-Laroche (Basel, Switzerland), low melting point aga-
rose from BRL (USA), polyvinyl chloride U microtiter plates
from Dynatech Laboratories (Alexandria, Virginia, USA), pu-
rified human fibrinogen, plasminogen, plasmin and a synthetic
substrate D-Val-Leu-Lys-pNA (S-2251) from AB Kabi (Stock-
holm, Sweden), human urokinase reference standard grade
from Choay (Paris, France), human t-PA, rabbit polyclonal
anti-human t-PA and anti-human u-PA antibodies from Biopool
(Sweden); H7, a protein kinase inhibitor, from Seikagaku-
Kogyoco Ltd. (Tokyo, Japan); lodogen, 1,3,4,6 tetrachloro 3a
6a diphenyl glycoluril from Pierce, Chemical Company, Illi-
nois, USA; alpha32P dCTP> 3000 Ci/mmol, from Amersham,
(United Kingdom). Polyclonal rabbit anti-PAL-I antibodies
were kindly provided by E.K.O. Kruithof (Lausanne, Switzer-
land).
Cell cultures
The LLC-PKI cell strain (passages 190-210) and the MDCK
cell strain (passages 80-90) were purchased from Flow Labora-
tories, Inc. (McLean, Virginia, USA).
The glomerular epithelial cells were cultured from normal
human kidneys (N = 10) judged to be unsuitable for transplan-
tation. Glomerular epithelial cells were obtained by collagenase
digestion of the isolated glomeruli, as previously described [27].
Briefly, glomeruli were isolated from renal cortex by differential
sieving through a 180 jim sieve to exclude vessels and tubules
and were then washed over a 105 jim sieve which allowed
cellular debris to pass through but retained glomeruli. Isolated
glomeruli were then suspended in Waymouth's medium (Flow
Laboratories, Irvine, UK) containing 500 U/mI coliagenase for
30 minutes at 37°C. The suspension was passed over a 25 p.m
sieve which retained partially digested glomeruli. Epithelial
cells in the filtrate were cultured at 37°C in Waymouth's
medium containing 20% pooled human serum in a humidified
atmosphere of 5% CO2 in air. They were identified by their
morphologic features and synthetic functions as previously
reported [27, 28]. By immunofluorescence, the epithelial origin
of these cells was further confirmed by the positive staining
with anti-cytokeratin antibodies; less than 10% of the cells had
a positive fluorescence when treated by anti-converting enzyme
antiserum, suggesting a possible low contamination of glomer-
ular cells by proximal tubular cells. All the cells contained
urokinase but not t-PA nor von Willebrand factor, excluding
mesangial and endothelial contamination, as previously re-
ported [15].
Incubation procedures
Incubations were performed on the third subculture of gb-
merular epithelial cells, or after more than 190 passages for
LLC-PKI and 80 passages for MDCK cells. They were per-
formed in multidish wells (Nuncbon, Nunc, Roskilde, Denmark)
before the cells reached confluence. Each well was washed
three times with serum-free Waymouth's medium to remove
serum plasminogen activators and plasminogen activator inhib-
itors. Adherent cells were incubated with the compound to be
tested or vehicle alone at 37°C in I ml of Waymouth's medium
in 5% CO2 atmosphere. At the end of incubation, the culture
media were collected separately for determination of plasmino-
gen activator activity. Cells were counted after detachment
with trypsin. Care was taken that the viability of the cells did
not differ between experimental and control conditions: in all
cases more than 95% of the cells excluded trypan blue dye. To
measure the intracellular content of u-PA, cellular lysats in 1%
Triton X 100 were studied.
Urokinase receptor binding assay
Purified human urokinase was iodinated with '251-Na (1 mCi)
in pH 7.4, 100 mM borate buffer. lodinated u-PA was separated
from non-incorporated 1251 by chromatography on Sephadex
050 column. Elution fractions (100 jil) were then aiialyzed by
SDS-PAGE and autoradiography. The fraction with the highest
53 kD 1251 u-PA signal was used from the binding assay,
corresponding approximately to 200,000 cpm per unit of u-PA.
Binding experiments were performed as described [19]. Adher-
ent glomerular epithelial cells (5. b04/plate) were washed with
Waymouth's medium containing 1 mg/mi bovine serum albu-
mine (BSA) and then incubated at 4°C with '251-u-PA in
Waymouth's medium containing 0.1 mg/mI BSA (approximate-
ly 1 to 2.10 cpm/plate corresponding to 200 to 400 1012 M
labeled ligand). At the end of incubation the supernatant was
removed, cells were washed three times with 1 mg/mI BSA
Waymouth's medium and cells were dissolved in I M NaOH
and counted in a gamma-ray counter. Each experiment was
carried out in duplicate. Specific binding was calculated by
subtracting the counts bound in the presence of 3.10 M
unlabeled u-PA. In order to unmask u-PA receptors, the cells
were treated for three minutes at 4°C with 50 mM glycine-HCI
buffer, pH 3. containing 0.1 M NaCI, then quickly neutralized
with 50 mtvi Hepes buffer (pH 7.5), 0.1 M NaCl, and washed
three times with Waymouth's medium containing I mg/mI BSA
as described [19]. Acid-treated cells were then subjected to the
binding assay in the absence or presence of competitor.
Electrophoretic procedures and zymography
SDS-polyacrilamide gel eiectrophoresis (SDS-PAGE) was
carried out according to Laemmli [291. The stacking and sepa-
rating gels contained 4% and 10% acrylamide, respectively. The
marker protein (Pharmacia, Uppsala, Sweden) was run for
molecular weight determination after gel staining with
Coomassie Blue dye. Commercial u-PA and t-PA were also run
in each gel. Zymography was carried out according to Loskutoff
[30]. Plasminogen activator activities of conditioned culture
medium were detected on a fibrin-agar underlay containing
plasminogen (fibrinogen 10 mg/mI, thrombin 300 mU/mi, agar-
ose 1% and plasminogen 20 jig/mI). Incubation was performed
at 37°C in humidified atmosphere. When indicated, samples to
be studied were diluted with anti-t-PA IgG, anti-u-PA IgG (15
p.gIml) or anti-PAIl dilution antiserum (1/10). After a 30-minute
incubation at 37°C, an aliquot of the antigen-antibody mixture
was analyzed by SDS PAGE and zymography.
Measurement of plasminogen activator activity
Samples were centrifuged (1500 g x 5 mm at 4°C) to remove
cellular debris. The supernatants were collected and Triton X
100 was added (final concentration 0.1%). Urokinase activity
was determined as previously described [15]. In brief, the
paranitroanilide liberated from the plasmin sensitive synthetic
chromogenic substrate D-Val-Leu-Lys-pNA 2 HC1 (S2251, AB
120—
73—
53—
33—
A
kd
1234 B'II 12
I.
W.V
34
e
S
Rondeau et a!: Urokinase receptors and epithelial cells 595
Fig. 1. A. Zymography of culture medium conditioned by glomerular
epithelial cells. Standard human u-PA (lane 1) and t-PA (lane 2) are
shown. The conditioned culture medium contained mainly a 53 kD form
of PA (lane 3) as well as a doublet with a Mr of 110 to 120 kD.
Stimulation of the cells by 16 nM PMA for 24 hours increased these
different molecular weight forms (lane 4). B. Immunoneutralization of
PA activities released by glomerular epithelial cells. As reported in
Methods, the conditioned culture medium was preincubated with spe-
cific antibodies and then analyzed by zymography. Conditioned culture
medium mixed with nonspecific goat IgG (final concentration 10 g/ml)
is shown in lane I. Anti-t-PA lgG (5 g/ml) inhibited the higher
molecular weight form (lane 2), anti-u-PA lgG (5 g/ml) inhibited the
two other forms (lane 3). In lane 4 anti-PAl-I antiserum (1/50 dilution)
inhibited the doublet of 110 to 120 kD.
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Fig. 2. A. Binding of '251-u-PA to human glomerular epithelial cells.
The binding by untreated cells (0) was low, but can be increased (•) by
acid buffer treatment of the cells as reported in Methods. Maximal
binding was reached after IS mm at 4°C. Each point represents the
mean of 2 separate experiments, expressed in cpm for 5.l0 cells. This
binding was specific and reversible since addition of 2. l0 M unlabeled
u-PA () resulted in a decrease of bound labeled u-PA (A). Standard
t-PA and thrombin at similar concentrations did not modify u-PA
binding (not shown). B. Competitive inhibition of labeled u-PA binding
by unlabeled u-PA and Scatchard plot analysis (inset). Each point
represents the mean of two separate experiments and binding is
expressed in cpm for 5.lO cells. Labeled (200 000 cpm/plate) and
unlabeled u-PA at various concentrations were simultaneously added,
and binding was measured after 15 mm at 4°C.
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Kabi, Stockholm, Sweden) was spectrophotometrically mea-
sured in microtiter polyvinylchloride plates. To detect total
u-PA activity, supernatants were incubated for two hours at
37°C with plasmin (final concentration 100 ng/ml) which trans-
forms the inactive pro-u-PA into the active form. In these cases
standard curves were made with commercial u-PA, also pre-
incubated with plasmin (100 ng/ml). The samples were tested in
a final volume of 100 Ml containing 1.2 p.g plasminogen and 0.5
mM S2251.
The absorbance at 405 nM was measured with a micro Elisa
counter after incubation at 37°C. For each experiment, the
absorbance of fresh Waymouth's medium containing 0.1%
Triton X 100, 0.5 mt S225l and 1.2 tg plasminogen, plus the
compound to be tested was measured and subtracted from the
corresponding value. These compounds had no direct effect on
the apparent enzymatic activity of exogenous urokinase mea-
sured by the chromogenic assay.
Northern blot analysis
After incubation of glomerular epithelial cells in serum-free
Waymouth's medium containing 16 nM PMA and/or 1 mrvi 8
bromo cyclic AMP, total RNA was extracted by the phenol-
chloroform method as described [31], and precipitated by Li Cl
3 M. After electrophoresis in 0.9% agarose gel containing 20%
formaldehyde (10 g of total RNA) and transfer to a nylon
membrane (Gene Screen Plus), hybridization was performed
using a specific alpha 32P labelled human u-PA cDNA probe as
described [31]. Autoradiograms were developed after 72 to 96
hours.
Statistical analysis
Results are expressed in units per 5.iO cells and mean +/—
SEM are given. Student t-test and two-way variance analysis
were used when appropriate.
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Fig. 3. Dose-response effect of PMA on active (A) and total (•) u-PA
activity in the culture medium of glomerular epithelial cells. Spontane-
ous u-PA activity was low whatever the concentration of PMA,
suggesting that u-PA was released in its inactive proenzyme form
(SC-u-PA). After preincubation with plasmin which activates SC-u-PA,
total u-PA activity was found to increase after stimulation of the cells by
PMA. Each point represents mean SEM of6 experiments performed
with 4 different glomerular cell preparations.
Results
Characterization of the plasminogen activator activity
produced by the renal cultured cells
The main plasminogen activator released by human glomer-
ular epithelial cells had an apparent molecular weight of 53 kD
comigrating with purified urokinase, and was neutralized by
anti-u-PA antibodies (Fig. 1). A doublet of higher molecular
weight forms of plasminogen activators, corresponding to 110
to 120 kD was also detected. With specific antibodies the 120
kD form corresponds to a complex made of t-PA and plasmin-
ogen activator inhibitor type I (PAl-I), since it was neutralized
by both anti-t-PA and anti-PAl-I antibodies and its molecular
weight (120 kD) fit with the sum of the known molecular weights
of t-PA (70 kD) and PAl-I (48 kD). The other form was
identified as a complex made of u-PA and PA!- I.
Evidence for u-PA receptors at the surface of glomerular
epithelial cells (Fig. 2)
Specific u-PA receptors could be demonstrated at the surface
of glomerular epithelial cells. This binding was saturable and
was low when cells were not pretreated by acid buffer. This
treatment has been shown to dissociate polypeptide ligands
from their receptors [321. After acid buffer treatment of glomer-
ular epithelial cells, more u-PA binding sites could be detected.
This binding was specific since unlabeled u-PA (2. l06 M)was
able to displace bound labeled u-PA whereas t-PA or thrombin
at similar concentrations did not (not shown). Competitive
inhibition of binding and Scatchard plot analysis (insert) gave
kD = 2. l0— M (mean of 2 separate experiments) and a receptor
concentration corresponding to 5.6 io sites per cell.
Urokinase release by cultured renal epithelial cells
Effect of phorbol myristic acetate. As shown in Figures 3 and
4, when cultures of human glomerular epithelial cells were
exposed to PMA, the level of plasminogen activator activity in
the conditioned medium rose markedly in a time- and dose-
dependent manner (by two-way analysis of variance F = 30.8,
P < 0,001 and F = 191.9, P < 0.0001). A significant interaction
(F 14.3, P < 0.0001, respectively) was observed between
these two parameters, indicating that the effect of PMA was
dependent on the duration of incubation. The percentage of
active to total u-PA was greater at 48 hours than for shorter
times of incubation, suggesting that SC-u-PA was activated in
the culture medium.
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Fig. 4. Ti,ne-course of u-PA activity in culture medium of glomerular
epithelial cells stimulated by PMA 16 nM. Active (A) and total u-PA (•)
are shown. The release of u-PA reached a plateau after 24 to 32 hours
of incubation. Activation of SC-u-PA into u-PA also seemed to occur in
the culture medium after prolonged incubation. Mean SEM are
represented (N = 3, from 3 individual cell preparations).
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Fig. S. Regulation of u-PA synthesis in glomerular epithelial cells.
PMA-stimulated u-PA release was inhibited in a dose-dependent man-
ner by ) H7, an inhibitor of protein kinase C (half-maximal inhibition
at 15 M) and (•) 8 bromo cyclic AMP (half-maximal inhibition at 200
/.tM). Absolute 100% value obtained after a 24 hours incubation with 16
nM PMA was 6.5 2.1 U/5.104 cells of total u-PA (N = 4), for
experiments with H7 and 5.8 0.3 U/5.l04 cells (N = 3) for experi-
ments with 8 bromo cAMP. Two individual cell preparations were used.
After a 24-hour incubation the total intracellular content of
u-PA was 0.25 0.04 U/S. l0 cells and increased to 0.40 0.12
U/5.104 cells when cells were stimulated by 16 nM PMA (N = 6,
= 1.15, P> 0.1), whereas the total u-PA activity released in
the conditioned culture medium rose from 1.4 0.3 to 5.8 0.3
U/S. io cells (N = 6, t = 10.47, P < 0.001). H7, a protein kinase
inhibitor, inhibited PMA stimulated u-PA synthesis in a dose-
dependent manner (Fig. 5). Half maximal inhibition by H7 was
observed at 15 /.LM, whereas no effect could be detected on the
basal production of u-PA by unstimulated glomerular epithelial
cells (not shown).
LLC-PKI and MDCK cells released mainly SC-u-PA which
could be detected after activation by plasmin. PMA (16 nM)
increased also u-PA release by MDCK (35.2 0.4 vs. 5.7 0.4
U/2.105 cells, N = 6, P <0.001) and by LLC-PK1 (11.7 3.5
vs. 3.65 0.80 U/7.l06 cells, N = 6, P < 0.05).
Effect of 8 bromo cyclic AMP. As shown in Figures 5 and 6,
in contrast to LLC-PKI, 8 bromo cyclic AMP did not increase
u-PA release by human glomerular epithelial cells and MDCK
cells. It inhibited the PMA-induced u-PA release to respectively
2.8 0.4 U/5.l04 cells for glomerular epithelial cells (P < 0.01
nfl
Basal PMA 8 br PMA
cAMP +
cAMP
Fig. 6. Regulation of u-PA synthesis in glomerular epithelia! cells,
LLC-PKI and MDCK cells. In all three cellular types PMA 16 nM
increased total u-PA activity in the culture medium (N = 6, P < 0.001);
8 bromo cyclic AMP, 1 m, also increased u-PA release by LLC-PKI
cells (N = 6, P < 0.001) but had rather an inhibitory, although non
significant, effect on glomerular epithelial cells (N = 3) and MDCK cells(N = 3). Finally, 8 bromo cyclic AMP inhibited significantly PMA-
stimulated u-PA release by glomerular epithelial cells and MDCK cells
(*P <0.01, and **P < 0.001, respectively). In LLC-PKI cells cAMP
increase the PMA-stimulated u-PA release but this effect was not
statistically significant.
when compared to the effect of PMA alone), and 9.8 0.1
U/2. iO cells for MDCK cells (P < 0.001 when compared to the
effect of PMA alone). No significant effect of 8 bromo cyclic
AMP was observed on the intracellular content of u-PA
whether or not the cells were stimulated by PMA.
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Fig. 7. Northern blot analysis of u-PA mRNA level with a 32P labeled
u-PA cDNA probe. In the upper part the effect of PMA, 16 nM, is
shown, after I, 2 and 4 hours of incubation, in the absence and in the
presence of 1 ms S bromo cyclic AMP. In the lower part, the time
course effect of 1 msi 8 bromo cyclic AMP on u-PA mRNA level is
shown.
Urokinase messenger RNA level (Northern blot analysis)
The stimulatory effect of PMA on u-PA synthesis by glomer-
ular epithelial cells was inhibited by alpha amanitin (more than
80% in two separate experiments), suggesting that de novo
mRNA synthesis was required.
Using a specific human urokinase cDNA probe, we studied
the effect of PMA (16 nM)and 8 bromo cyclic AMP (1 mM) on
the steady state level of u-PA mRNA in human glomerular
epithelial cells. As shown in Figure 7, PMA induced a marked
increase of u-PA mRNA after two and four hours. Addition of
8 bromo cyclic AMP to PMA did not inhibit PMA induction of
u-PA, mRNA at two hours, but prevented further increase at
four hours; this suggests that cAMP in these cells does not
interfere with u-PA gene transcription but rather with mRNA
stability. When 8 bromo cyclic AMP was used alone, a decrease
of u-PA mRNA level was obvious after 4 to 24 hours of
incubation.
Discussion
We demonstrate here that human glomerular epithelial cells
possess specific plasma membrane binding sites for u-PA and
that these cells synthesize pro-u-PA. Pro-u-PA has been shown
to bind very efficiently to u-PA receptors [1, 18, 19]. As in
human epidermoid carcinoma-derived A 431 and fibrosarcoma
HT 1080 cells [18, 331 uncovering of u-PA receptors can be
achieved by dissociation of u-PA from the cell surface by short
exposure to low pH conditions. This demonstrates that pro-
u-PA secreted by glomerular epithelial cells can bind to the
membrane u-PA receptor. This receptor seems to have a 10
times lower affinity than described for other cells but the
number of sites/cell is similar [1, 181. It has been shown that
bound pro-u-PA can be activated to the two-chain active form
[34], that bound active u-PA is protected from certain inhibitors
and that it is responsible for a plasminogen-dependent pericel-
lular proteolytic activity [1].
This may be particularly important for glomerular epithelial
cells to prevent clot formation in the urinary space of the
glomerulus. Pathological conditions, such as extracapillary
glomerulonephritis, are characterized by epithelial cell and
macrophage accumulation in the urinary space. Fibrin deposits
are also frequently observed in these cases, suggesting a defect
in local fibrinolytic activity. Peripheral blood monocytes have
specific u-PA receptors and synthesize low amounts of u-PA
and an inhibitor, PAI2, when stimulated [20, 211. Studies are
required to elucidate why fibrin deposits persist in these glom-
erulonephritides.
One explanation would be a decrease in u-PA synthesis by
glomerular epithelial cells. The regulation of u-PA synthesis by
these cells has not been reported before. We demonstrate here
that PMA increases u-PA synthesis by glomerular epithelial
cells and that this effect is probably mediated by protein kinase
C activation since it was inhibited by H7, a known inhibitor of
intracellular protein kinases [35]. The half-maximal inhibition
was observed with 15 LM H7, not very different from the IC 50
of 7 /.LM reported for purified protein kinase C. Furthermore, for
the first time in these cells, the steady state level of u-PA
mRNA was shown to increase markedly after stimulation by
PMA, probably through an increased u-PA gene transcription,
as reported in LLC-PK1 [22]. In LLC-PK1, u-PA gene tran-
scription can be increased also by peptide hormones known to
enhance the intracellular level of cyclic AMP or by exogenous
8 bromo cyclic AMP [25, 26]. Conversely, the PMA-stimulated
release of u-PA by glomerular epithelial cells and by MDCK
was inhibited by cyclic AMP. Since there was no increase of the
intracellular u-PA content, it is likely that activation of protein
kinase A by cyclic AMP in glomerular epithelial cells, as in
MDCK, inhibited u-PA synthesis. The inhibitory effect of cyclic
AMP on u-PA synthesis by glomerular epithelial cells seems to
be mediated by an increased mRNA degradation. It did not
inhibit the early PMA-induced u-PA mRNA increase, suggest-
ing that it did not affect u-PA gene transcription in these cells.
A cell specificity for u-PA gene regulation by cyclic AMP has
been reported by others [36]. Thus hormones or local mediators
which can regulate the cyclic AMP and the protein kinase C
pathways in these cells could regulate the local fibrinolytic
activity.
An other explanation for the persistance of fibrin deposits in
the urinary space of the glomerulus would be a defect in
pro-u-PA activation. Little is known about this process. Plas-
mm, bradykinin and probably u-PA itself can cleave pro-u-PA
to active u-PA [I]. It is likely that glomerular epithelial cells
release a proteolytic activity able to activate pro-u-PA, since
the percentage of active to total u-PA rises with time in the
conditioned culture medium.
Finally, fibrin deposits may persist if there isa local increase
in u-PA inhibitors. We found that human glomerular epithelial
cells release PAl-i, found in a complexed form to t-PA and
u-PA. Regulation of PAl-I synthesis by these cells is not known
and further studies are needed. We failed to demonstrate t-PA
by indirect immunolluorescence in glomerular epithelial cells
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[15]. This discrepancy between zymography and immunofluo-
rescence may be explained by a difference in sensitivity be-
tween the two methods and/or by a differentiation of epithelial
cells in culture as reported for other cells [37]. A contamination
of the culture by glomerular endothelial cells seem unlikely
since these cells are very difficult to obtain in culture and since
no fluorescence could be observed with anti-von Willebrand
factor.
In conclusion, human glomerular epithelial cells in culture
synthesize and release mainly SC-u-PA which can bind to
specific membrane u-PA receptors. This release can be stimu-
lated by PMA, as in LLC-PKI and MDCK cells, probably
through protein kinase C activation and increased u-PA gene
transcription. The PMA effect is inhibited by cyclic AMP which
probably increase u-PA mRNA degradation in human glomer-
ular epithelial cells. This pericellular proteolytic activity could
prevent fibrin deposition in the urinary space of the glomerulus
and may be defective in extracapillary glomerulonephritis.
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